Key Highlights of the report
How are the major segments performing in the Osteoporosis Drugs Market?
- In 2022, Selective Estrogen Inhibitors Modulator (SERM) dominated the drug class segment as it can mimic and block estrogen's effect on different tissues by interacting with estrogen receptors in different cells.
- In 2022, the injectable segment was anticipated to hold a prominent share of the global osteoporosis drugs market. As injectable drugs can be taken longer than oral ones and more people find it easy to have injectable medicine as it does not upset the stomach, this segment will grow.
What is the Market Size of Osteoporosis Drugs regarding value?
The global osteoporosis drugs market is anticipated to grow at a substantial CAGR of 5.5% in the upcoming years. The global osteoporosis drugs industry was estimated to be worth USD 15.1 billion in 2022 and was expected to be worth USD 21.9 billion by 2028.
Which region dominated the Osteoporosis Drugs Market?
In 2022, North America dominated the osteoporosis drugs market; with a growing population, surging cases of obesity and increasing lifestyle-related diseases, the region dominates the osteoporosis drugs market. A survey found out 34 million Americans have inadequate bone density and are at high risk of fracture. Out of these, 30% of people are suffering from the problem of osteoporosis. The region is dominating with the increase in government regulations to prevent and protect the disease from spreading and finding the cure properly.
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Osteoporosis Drugs Market by Volume | Yes |
| Osteoporosis Drugs Market by Value | Yes |
| Osteoporosis Drugs Market, Tornado Analysis | Yes |
| Osteoporosis Drugs Market, STAR Analysis | Yes |
| Osteoporosis Drugs Market, SRC Analysis | Yes |
| Osteoporosis Drugs Market, Import-Export Data | Yes (On Demand) |
| Osteoporosis Drugs Market Pricing Analysis | Yes (On Demand) |
| Osteoporosis Drugs Market Segment Analysis | By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others) By Route of Administration (Oral, Injectable, Others) |
| Osteoporosis Drugs Market, Regional Analysis | North America (US and Canada) Europe (Germany, UK, France, Italy, Spain, and the Rest of Europe) Asia Pacific (China, India, Japan, South Korea, South East Asia, and the Rest of Asia Pacific) Latin America (Brazil, Mexico, and the Rest of Latin America) Middle East and Africa (GCC Countries, South Africa, and the Rest of the Middle East and Africa) |
| Osteoporosis Drugs Market Key Companies | Amgen Inc., F. Hoffmann-La Roche AG, Radius Health, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. |
| Osteoporosis Drugs Market Competitive Landscape | Market Share Analysis Competitive Benchmarking Key Players Market Positioning Geographical Presence Analysis Major Strategies Adopted |
How is US Market Performing in the Osteoporosis Drugs Market?
In 2022, around 1.5 million people faced the problem of osteoporosis and fracture in the U.S. Every year, the use of osteoporosis drugs is high in the country as to the healthcare agencies' sanctions and guidelines for the patients suffering from the disease. With the change in lifestyle, the increase in healthcare expenditure, and regular research and development work, the growth in osteoporosis care units in the country is growing the fastest in the market worldwide.
How is the Economy Impacting Global Osteoporosis Drugs market growth?
With the leading economic indicators and the government's spending a significant share on healthcare infrastructure, the osteoporosis drugs market will grow rapidly. An increasing number of hospitals and clinics, and pharmacies. The drug manufacturers are funded. Various brands of medicines are available for people to choose from according to their spending. The market is growing quickly worldwide. The number of healthcare workers is increasing in numbers, and research and development are always funded for constant drug development.
What is the competitive environment of the Osteoporosis Drugs market?
The global osteoporosis market is highly competitive; therefore, the major players have adopted several strategies to gain maximum market share. There have been collaborations, mergers, acquisitions and new product launches by the players in the market. The companies are constantly working on their research sections to develop and update the drug qualities with time.
Executive Summary
What are the key trends in the Osteoporosis Drugs Market?
- In 2022, advances in the molecular comprehension of bone metabolism and bioengineering will help find new ways to treat osteoporosis in the future, with the help of paradigms like antibody therapeutics, gene therapies and stem cell therapies.
- In 2021, because of the developments in pharmaceutical research in the field of osteoporosis, a personalized therapeutic setting will help the selection of the most suitable and effective treatment for the disease with the lowest amount of detrimental effects.
How are Osteoporosis Drugs used to treat the disease?
With the help of lifestyle changes, osteoporosis drugs work the best. There are various steps by which these drugs are given to patients. Usually, bisphosphonates are given for osteoporosis treatment, including alendronate risedronate and others. Another common medication for osteoporosis is denosumab, which might be used for people who cannot take bisphosphonate due to allergies or reduced kidney function. Denosumab is delivered with the help of shallow injections, just under the skin and every six months. Stopping this drug have serious consequences like spinal cord fracture; therefore, the doctors advice taking medicine consistently. There are both intravenous as well as oral medications available for the patients. These medications reduce the rate at which the bones break down by speeding up the bone-building processes.
Which are the key investments by the Osteoporosis Drugs market players?
Market players are focusing on research and development to improve the market for the end-use industries. For instance, in April 2020, Amgen Inc. got U.S. FDA approval for its drug EVENITY to treat osteoporosis in postmenopausal women at high risk for fractures. In August 2019, Radius Health, Inc. started the Phase 3 wearABLe Study in its research section for treating Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at very high risk for fracture.
Some major digital diagnostics players are Amgen Inc., F. Hoffmann-La Roche AG, Radius Health, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
What are the Major Driving Factors for the Osteoporosis Drugs Market?
With the increase in the per capita income of the people, their expenditure is in different areas. People have started focusing on their health and paying attention to improving it. Therefore the increase in healthcare expenditure will be the major driver of the market. With the surge in the prevalence of different types of diseases and rising government initiatives for people's health and the improvement in healthcare infrastructure and increasing the affordability of treatment and diagnosis for various medical conditions, the market is set to grow rapidly. As the governments in different countries are investing a significant amount of GDP in healthcare, in developed and developing countries like the U.S. in North America and India in Asia and the guidelines by WHO to maintain the people's health, this trend will drive the market.
What are the Major Risks for the Osteoporosis Drugs Market?
Adverse effects of the drugs are restraining the growth of the market. The rise in healthcare awareness and new technologies that can replace drugs are the factors that can restrain the market. The factors such as the patent expiry of the drugs, as well as the adverse effects of the drugs, are the factors that are hindering the growth. The side effects of the anti-inflammatory drugs are their slow efficacy, and other side effects of the osteoporosis drugs, such as vomiting, leg cramps, diarrhea and others, are also restraining the market.
Which is the key platform in the Osteoporosis Drugs market?
During the forecast period, the Selective Estrogen Inhibitors Modulator (SERM) dominated the drug class segment as it can mimic and block estrogen's effect on different tissues by interacting with estrogen receptors in different cells. It increases bone density by 2 to 3 percent in the lower hips and spine. It also reduces spinal fractures by upto 50 percent and 22 percent in other regions.
How is the Osteoporosis Drugs market performing in regions?
The greatest revenue share in the Osteoporosis Drugs market was attributed to North America. Easy availability of osteoporosis drugs and surge in healthcare advancement, the technical advancement in the detection of the disease and further the cure of it. The research and development in the orthopedic department. With the growing number of cases of the disease due to the busy lifestyle of people, the market for osteoporosis drugs in the regions will be growing significantly. On the other hand, the Asia Pacific market is expected to grow significantly in the forecasted years. The consistent R&D investment in the healthcare sector in this region and the presence of prominent players in developing economies like India and China, and their efforts to commercialize branded medicines at relatively low prices are driving the market in the region.
What is the regulatory landscape for the Osteoporosis Drugs market?
As stated by FDA, the Guidelines for the Clinical Evaluation of Drugs Used in the treatment of osteoporosis will help find a more accurate cure for the disease. FDA and EMA both have established guidance documents on conducting osteoporosis clinical trials. These trials' objective is to develop a drug treatment for osteoporosis. As outlined in 1994 FDA guidelines for osteoporosis trials, the approval included; normal bone quality in a subset of clinical trial participants, normal bone quality in preclinical studies of two animal species, and a clinical and significant increase in bone mineral density.
What are the major players planning for the future of the Osteoporosis Drugs market?
In April 2020, Amgen Inc. got U.S. FDA approval for its drug EVENITY (romosozumab-aqqg) for treating osteoporosis in postmenopausal women at high risk for fracture. In August 2019, Radius Health, Inc. started the Phase 3 wearABLe Study in its research section for treating Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at very high risk for fracture.
Segmentation of Global Osteoporosis Drugs Market-
Global Digital Diagnostics Market – By Drug Class
- Bisphosphonates
- Selective Estrogen Inhibitors Modulator (SERM)
- Parathyroid Hormone Therapy
- Calcitonin
- Rank Ligand Inhibitors
- Others
Global Digital Diagnostics Market – By Route of Administration
- Oral
- Injectable
- Other
Global Digital Diagnostics Market – By Region
- North America
- U.S
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Request a Free Sample
Fill in your details and we'll send you a free sample report.
- Sample data tables & charts
- Research methodology
Market Dynamics
Rising Healthcare Expenditure and Infrastructure
Increasing per capita income and government investment in healthcare infrastructure are enabling broader access to osteoporosis diagnosis and treatment, driving market growth as more patients are able to afford and receive osteoporosis drugs.
Growing Prevalence of Osteoporosis and Lifestyle Diseases
The surge in osteoporosis cases, particularly in aging populations and regions with rising obesity and sedentary lifestyles, is directly increasing demand for effective osteoporosis drug therapies.
Advancements in Drug Development and Personalized Medicine
Ongoing research and development, including the introduction of new drug classes, antibody therapeutics, and personalized treatment regimens, are expanding the therapeutic options available and improving patient outcomes, fueling market expansion.
Supportive Regulatory and Government Initiatives
Government regulations and guidelines, such as those from the FDA and EMA, are streamlining clinical trials and approvals for osteoporosis drugs, while public health initiatives are raising awareness and encouraging early intervention, further boosting market growth.
Need a Custom Version of This Report?
Tailor the scope, geography, or segments to your exact requirements.
- Custom geography or segment scope
- Direct access to our analyst team
Frequently Asked Questions
How does COVID-19 Impact the global Osteoporosis Drugs market?
Which is the leading region of the market for Osteoporosis Drugs?
What are the key drivers for the growth of the Osteoporosis Drugs market?
Which is the major segment in the digital diagnostics market by drug class?
Which is the major segment in the digital diagnostics market by the Route of Administration industry?
Table of Content
Chapter 1 Market Segmentation
- 1.1 Segmentation Framework
- 1.1.1 Product and Service Classification
- 1.1.2 Application and End-Use Classification
- 1.1.3 Technology and Solution Classification
- 1.1.4 Customer and Distribution Channel Classification
- 1.1.5 Geographic Segmentation
- 1.1.6 Market Segment Definitions and Boundaries
- 1.2 By Drug Class
- 1.2.1 Bisphosphonates
- 1.2.2 Selective Estrogen Inhibitors Modulator (SERM)
- 1.2.3 Parathyroid Hormone Therapy
- 1.2.4 Calcitonin
- 1.2.5 Rank Ligand Inhibitors
- 1.2.6 Others
- 1.3 By Route of Administration
- 1.3.1 Oral
- 1.3.2 Injectable
- 1.3.3 Other
Chapter 2 Introduction
- 2.1 Report Objectives and Scope
- 2.2 Product Definition and Industry Terminology
- 2.3 Market Inclusions and Exclusions
- 2.4 Research Process
- 2.4.1 Primary Research and Expert Interviews
- 2.4.2 Secondary Research and Source Review
- 2.4.3 Top-Down and Bottom-Up Estimation
- 2.4.4 Data Triangulation and Verification
- 2.5 Research Assumptions and Limitations
Chapter 3 Executive Summary
- 3.1 Market Snapshot and Key Findings
- 3.2 Base-Year Market Size
- 3.3 Forecast Market Size
- 3.4 Revenue and Volume Growth Outlook
- 3.5 Key Demand and Supply Indicators
- 3.6 Leading Market Segments
- 3.7 Fastest-Growing Market Opportunities
- 3.8 Regional Performance Highlights
- 3.9 Technology and Industry Transformation
- 3.10 Competitive Landscape Summary
- 3.11 Analyst View and Strategic Implications
Chapter 4 Global Osteoporosis Drugs Market Trends and Developments
- 4.1 Historical Industry Development
- 4.2 Recent Market Trends and Developments
- 4.3 Demand and Customer Behavior Trends
- 4.4 Technology and Product Innovation
- 4.5 Artificial Intelligence, Automation and Digitalization
- 4.6 Local Manufacturing and Supply Chain Realignment
- 4.7 Industry Partnerships, Mergers and Acquisitions
- 4.8 Sustainability and Circular Economy Developments
- 4.9 Government and Private Sector Investment Trends
- 4.10 Emerging Business Models and Commercialization
- 4.11 Industry Developments and Announcements
Chapter 5 Global Osteoporosis Drugs Market Production, Supply and Demand Analysis
- 5.1 Demand Trend and Consumption Analysis
- 5.2 Demand Forecast
- 5.3 Production and Output Trend
- 5.4 Production and Output Forecast
- 5.5 Installed Capacity and Capacity Utilization
- 5.6 Company-Wise Production Plants and Statistics
- 5.6.1 Installed Production Capacity
- 5.6.2 Actual Production
- 5.6.3 Planned Capacity and Expansion Targets
- 5.7 Supply Chain Structure and Procurement Trends
- 5.8 Supply-Demand Gap and Bottlenecks
- 5.9 Import Dependence and Sourcing Structure
- 5.10 Contract Manufacturing and Outsourcing
- 5.11 Regional Supply and Demand Concentration
Chapter 6 Global Osteoporosis Drugs Market Pricing Analysis
- 6.1 Pricing Structure and Measurement
- 6.2 Historical Pricing Trends
- 6.3 Pricing Outlook
- 6.4 Average Selling Price and Unit Economics
- 6.5 Pricing by Product and Market Segment
- 6.6 Geographic Pricing Differences
- 6.7 Key Input, Energy, Labor and Logistics Costs
- 6.8 Contract Pricing and Purchasing Models
- 6.9 Pricing Sensitivity and Competitive Positioning
- 6.10 Price, Margin and Profitability Implications
Chapter 7 Global Osteoporosis Drugs Market Dynamics
- 7.1 Market Growth Drivers
- 7.1.1 Demand-Side Drivers
- 7.1.2 Technology and Innovation Drivers
- 7.1.3 Infrastructure and Investment Drivers
- 7.1.4 Regulatory and Policy Drivers
- 7.2 Market Restraints
- 7.2.1 Cost and Affordability Constraints
- 7.2.2 Technology and Adoption Barriers
- 7.2.3 Supply Chain and Operational Constraints
- 7.3 Market Challenges
- 7.3.1 Competitive Pressure and Margin Erosion
- 7.3.2 Skills, Infrastructure and Implementation Gaps
- 7.4 Emerging Market Opportunities
- 7.5 Market Dynamics Impact and Time-Horizon Assessment
Chapter 8 Global Osteoporosis Drugs Value Chain Analysis
- 8.1 Industry Value Chain Overview
- 8.2 Upstream Suppliers and Critical Inputs
- 8.3 Technology and Component Providers
- 8.4 Manufacturing or Service Delivery
- 8.5 Distribution, Channel Partners and Integrators
- 8.6 Downstream Applications and End Users
- 8.7 Value Addition and Profit Pools
- 8.8 Vertical Integration and Outsourcing
- 8.9 Supplier Concentration and Risk
- 8.10 Supply Chain Localization and Resilience
Chapter 9 Global Osteoporosis Drugs Market Regulations and Policies
- 9.1 Relevant Laws, Standards and Compliance Frameworks
- 9.2 Product, Service, Safety and Quality Requirements
- 9.3 Government Policies, Incentives and Subsidies
- 9.4 Imports, Exports and Trade Barriers
- 9.5 Public Procurement and Local Content Requirements
- 9.6 Environmental and Sustainability Compliance
- 9.7 Upcoming Policy Changes and Market Implications
Chapter 10 Global Osteoporosis Drugs Market Hotspots and Opportunities
- 10.1 Market Opportunity Mapping and Growth Hotspots
- 10.2 High-Growth Applications and Customer Groups
- 10.3 Underserved Markets and White-Space Opportunities
- 10.4 Emerging Technology and Product Opportunities
- 10.5 New Capacity and Investment Hotspots
- 10.6 Market Entry and Expansion Opportunities
- 10.7 Distribution and Partnership Opportunities
- 10.8 Near-Term and Long-Term Commercial Potential
- 10.9 Opportunity Attractiveness and Execution Risks
Chapter 11 Global Osteoporosis Drugs Market Outlook
- 11.1 Market Size and Analysis
- 11.1.1 Revenue
- 11.1.2 Market Volume and Quantity Sold
- 11.1.3 Historical Market Size
- 11.1.4 Base-Year Market Size
- 11.2 Market Forecast
- 11.2.1 Revenue Forecast
- 11.2.2 Volume Forecast
- 11.2.3 CAGR and Year-on-Year Growth
- 11.2.4 Incremental Revenue Opportunity
- 11.3 Forecast Assumptions and Scenario Analysis
- 11.3.1 Base-Case Forecast
- 11.3.2 Optimistic and Conservative Scenarios
- 11.3.3 Technology, Pricing and Policy Sensitivities
- 11.4 Market Attractiveness and Growth Outlook
Chapter 12 Global Osteoporosis Drugs Market Segmentation and Outlook
- 12.1 Segmentation Summary and Market Shares
- 12.2 Largest and Fastest-Growing Segments
- 12.3 By Drug Class - Market Size and Forecast
- 12.3.1 Segment Definition and Scope
- 12.3.2 Historical Market Size
- 12.3.3 Revenue Forecast
- 12.3.4 Volume Forecast
- 12.3.5 Base-Year Market Share
- 12.3.6 Segment CAGR and Growth Drivers
- 12.3.7 Subsegment Market Size and Forecast
- 12.3.7.1 Bisphosphonates
- 12.3.7.2 Selective Estrogen Inhibitors Modulator (SERM)
- 12.3.7.3 Parathyroid Hormone Therapy
- 12.3.7.4 Calcitonin
- 12.3.7.5 Rank Ligand Inhibitors
- 12.3.7.6 Others
- 12.3.8 Subsegment Pricing and Adoption Trends
- 12.3.9 Leading Suppliers and Competition
- 12.3.10 Regional Demand and Opportunities
- 12.4 By Route of Administration - Market Size and Forecast
- 12.4.1 Segment Definition and Scope
- 12.4.2 Historical Market Size
- 12.4.3 Revenue Forecast
- 12.4.4 Volume Forecast
- 12.4.5 Base-Year Market Share
- 12.4.6 Segment CAGR and Growth Drivers
- 12.4.7 Subsegment Market Size and Forecast
- 12.4.7.1 Oral
- 12.4.7.2 Injectable
- 12.4.7.3 Other
- 12.4.8 Subsegment Pricing and Adoption Trends
- 12.4.9 Leading Suppliers and Competition
- 12.4.10 Regional Demand and Opportunities
- 12.5 Segment Growth Comparison
- 12.6 Segment Attractiveness and Priority Matrix
Chapter 13 Global Osteoporosis Drugs Geographic Market Outlook
- 13.1 Regional Market Size and Share
- 13.2 Regional Market Forecast
- 13.3 Regional Pricing, Production and Demand Differences
- 13.4 North America
- 13.4.1 United States
- 13.4.2 Canada
- 13.4.3 Mexico
- 13.5 Europe
- 13.5.1 Germany
- 13.5.2 France
- 13.5.3 Italy
- 13.5.4 United Kingdom
- 13.5.5 Spain
- 13.5.6 Poland
- 13.5.7 Russia
- 13.5.8 Netherlands
- 13.5.9 Belgium
- 13.5.10 Sweden
- 13.5.11 Denmark
- 13.5.12 Norway
- 13.5.13 Rest of Europe
- 13.6 Asia Pacific
- 13.6.1 China
- 13.6.2 India
- 13.6.3 Japan
- 13.6.4 South Korea
- 13.6.5 Thailand
- 13.6.6 Indonesia
- 13.6.7 Vietnam
- 13.6.8 Malaysia
- 13.6.9 Australia
- 13.6.10 Rest of Asia Pacific
- 13.7 Latin America
- 13.7.1 Brazil
- 13.7.2 Argentina
- 13.7.3 Colombia
- 13.7.4 Chile
- 13.7.5 Rest of Latin America
- 13.8 Middle East
- 13.8.1 Saudi Arabia
- 13.8.2 United Arab Emirates
- 13.8.3 Turkey
- 13.8.4 Israel
- 13.8.5 Iran
- 13.8.6 Rest of the Middle East
- 13.9 Africa
- 13.9.1 South Africa
- 13.9.2 Egypt
- 13.9.3 Nigeria
- 13.9.4 Morocco
- 13.9.5 Rest of Africa
- 13.10 Regional Investment, Policy and Supply Chain Differences
- 13.11 Regional Competitive Landscape
- 13.12 Geographic Growth Hotspots
Chapter 14 Global Osteoporosis Drugs Technology, Innovation and Sustainability Outlook
- 14.1 Technology Landscape and Maturity
- 14.2 Product, Process and Service Innovation
- 14.3 AI, Automation and Digital Tools in the Industry
- 14.4 Technology Adoption and Performance Benchmarking
- 14.5 Innovation Pipeline and R&D Investment
- 14.6 Patent and Intellectual Property Trends
- 14.7 Energy Efficiency and Resource Management
- 14.8 Sustainability, Recycling and Circularity
- 14.9 Technology Roadmap
- 14.10 Risks of Obsolescence and Technology Substitution
Chapter 15 Global Osteoporosis Drugs Market Key Strategic Imperatives
- 15.1 Growth and Market Entry Priorities
- 15.2 High-Return Products and Segments
- 15.3 Pricing, Profitability and Cost Optimization
- 15.4 Technology Investment and Product Differentiation
- 15.5 Supply Chain Localization and Resilience
- 15.6 Distribution and Customer Acquisition
- 15.7 Partnership, Acquisition and Capacity Strategy
- 15.8 Regional Expansion Priorities
- 15.9 Short-, Medium- and Long-Term Actions
Chapter 16 Competition Outlook
- 16.1 Industry Competition Characteristics
- 16.2 Market Structure and Concentration
- 16.3 Market Share and Competitive Positioning
- 16.4 Company-Wise Revenue and Product Benchmarking
- 16.5 Production and Service Capacity Benchmarking
- 16.6 Technology, Pricing and Differentiation
- 16.7 Regional Footprint and Distribution Strength
- 16.8 Mergers, Acquisitions and Strategic Alliances
- 16.9 New Entrants and Competitive Threats
- 16.10 Porter's Five Forces and Industry Attractiveness
- 16.11 Competitive Outlook
Chapter 17 Company Profiles
- 17.1 Company Coverage and Selection Criteria
- 17.2 Amgen Inc.
- 17.2.1 Business Description
- 17.2.2 Company Ownership and Geographic Presence
- 17.2.3 Product and Service Portfolio
- 17.2.4 Manufacturing and Operating Footprint
- 17.2.5 Production Capacity and Expansion Plans
- 17.2.6 Financial Performance and Investment
- 17.2.7 Market Share and Competitive Position
- 17.2.8 Technology and Innovation Capabilities
- 17.2.9 Strategic Alliances or Partnerships
- 17.2.10 Recent Developments
- 17.2.11 Growth Strategy and Outlook
- 17.3 F. Hoffmann-La Roche AG
- 17.4 Radius Health, Inc.
- 17.5 Merck & Co. Inc.
- 17.6 Novartis International AG (Sandoz)
- 17.7 Pfizer Inc.
- 17.8 Sun Pharmaceutical Industries Ltd.
- 17.9 Takeda Pharmaceutical Company Limited
- 17.10 Teva Pharmaceutical Industries Ltd.
- 17.11 Other Relevant Market Participants
Note: Every listed company is profiled on the structure shown under the first company. The company list is preliminary and may change based on research findings, market developments, data availability and client requirements.
Chapter 18 Disclaimer
- 18.1 Research and Forecast Disclaimer
- 18.2 Data Source and Estimation Limitations
Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.
